Gatifloxacin
- Generic Name
- Gatifloxacin
- Brand Names
- Zymar, Zymaxid
- Drug Type
- Small Molecule
- Chemical Formula
- C19H22FN3O4
- CAS Number
- 112811-59-3
- Unique Ingredient Identifier
- 81485Y3A9A
- Background
Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in vari...
- Indication
For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes
- Associated Conditions
- Bacterial Conjunctivitis, Ocular Infections, Irritations and Inflammations
- Associated Therapies
- -
One Hour Preoperative Gatifloxacin
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 60
- Registration Number
- NCT00350363
- Locations
- 🇺🇸
Stanford, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.